A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (D-VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-Dose Therapy.

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

StatusActive
Effective start/end date13/02/1929/02/24